HOME >> BIOLOGY >> NEWS
Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

vel higher than previously known for staph. It was the first time that the possibility of a strain of bacteria resistant to any antibiotic had appeared since penicillin became widely used in the 1940s.

In order for disease to result from bacterial infection, the expression of a series of genes must occur, allowing the prospective pathogen to adapt to the hostile environment in the host. Because this gene expression contributes to the virulence of the pathogens, the products encoded by the genes are referred to as "virulence factors." These factors contribute to the microorganism's ability to survive and grow at the site of the infection.

According to Hoch, "Impairment of one or more of these virulence factors by mutation, antibody neutralization or chemical inhibition can be the determining factor in tipping the outcome of the infection favorably toward the host. As a consequence, we are gaining an appreciation for the potential usefulness of bacterial virulence factors as new targets for therapeutic intervention against antimicrobial resistant pathogens. Two-component signal transduction systems are the only common regulatory elements shared by a wide range of virulence systems, raising the possibility that a broad spectrum inhibitor to such elements may suppress virulence in a variety of microorganisms."

This study shows the efficacy of the compound RWJ-49815 and its derivatives as the first series of inhibitors of two-component systems with demonstrated bactericidal activity against a broad range of microorganisms. The scientists are hopeful that these inhibitors targeting the signal transduction mechanisms will be useful new tools in the armamentarium against infectious disease. They speculate that human clinical trials could begin in two to three years.

Funding for the study was made possible by Johnson & Johnson and the National Institutes of Health.


'"/>

Contact: Robin B. Goldsmith
rgoldsmi@scripps.edu
(619) 784-8134
Scripps Research Institute
28-Apr-1998


Page: 1 2

Related biology news :

1. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
2. Scientists sequence genome of kind of organism central to biospheres carbon cycle
3. Scientists find nanowires capable of detecting individual viruses
4. Scientists discover potential new way to control drug-resistant bacteria
5. Scientists explore genome of methane-breathing microbe
6. Scientists decipher genetic code of biothreat pathogen
7. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
8. Scientists discover proteins involved in spread of HIV-1 infection
9. Scientists fear new Ebola outbreak may explain sudden gorilla disappearance
10. Scientists reinvent DNA as template to produce organic molecules
11. Scientists visualise cellular handmaiden that restores shape to proteins

Post Your Comments:
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
(Date:3/3/2015)... Experts and industry insiders from around the ... Alltech REBELation exploring innovation, inspiration and world-changing ideas in ... 31st year, Alltech’s annual international conference traditionally draws more ... to join the REBELation at an extra discount registration ... at which point the standard early registration rate will ...
(Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
Cached News: